RelabotulinumtoxinA (QM1114)

About Galderma Group

Galderma's mission is to advance dermatology for every skin story, leveraging its position as the sole global, scaled pure-play in the field. Its key achievement is building an integrated, three-pillar business model—Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare—that drives growth across medical and consumer markets. The strategy centers on innovation through a proprietary R&D engine, global commercial execution, and capitalizing on its independence post-2019 Nestlé separation and successful 2024 IPO. This approach has established a leading portfolio with strong brand recognition and a robust pipeline.

Therapeutic Areas

Other Aesthetic Indications Drugs